Breast Cancer Clinical Trial
Official title:
The Efficacy of Acupuncture and Self-acupuncture in Managing Cancer-related Fatigue in Breast Cancer Patients: a Pragmatic Randomised Trial
Verified date | August 2009 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Acupuncture may help relieve fatigue caused by breast cancer. It is not yet known
whether acupuncture is more effective than self-acupuncture in managing fatigue in women
with breast cancer.
PURPOSE: This randomized phase III trial is studying acupuncture to see how well it works
compared with self-acupuncture in managing cancer-related fatigue in women who have received
chemotherapy for stage I, stage II, or stage IIIA breast cancer.
Status | Completed |
Enrollment | 320 |
Est. completion date | February 2013 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of breast cancer - Stage I, II, or IIIA disease - Completed prior chemotherapy for = 1 month and up to 5 years - No needling on the ipsilateral arm of patients who have undergone axillary dissection - No needling on the lymphedematous limbs - Score of = 5 on a 0-10 single-item screening fatigue scale, where 0 is no fatigue at all and 10 is extremely fatigued - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Life expectancy = 6 months - Menopausal status not specified - Platelet count = 50,000/mm^3 - Hemoglobin = 10 g/dL - Hematocrit = 30% - Not pregnant - No needle phobia - No co-morbidity with any of the following: - Bleeding disorder - Thyroid dysfunction PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No planned concurrent chemoradiotherapy - No concurrent steroids - No concurrent epoetin alfa or transfusion for anemia - No other concurrent complementary therapies |
Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Manchester | Manchester | England |
Lead Sponsor | Collaborator |
---|---|
University of Manchester |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | General fatigue as measured by the Multidimensional Fatigue Inventory | No | ||
Secondary | Mental fatigue as measured by the Multidimensional Fatigue Inventory | No | ||
Secondary | Anxiety as measured by the Hospital Anxiety and Depression Scale | No | ||
Secondary | Depression as measured by the Hospital Anxiety and Depression Scale | No | ||
Secondary | Quality of life as measured by the FACT-G and Breast Cancer module | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |